1. Since 1 November 2018, how many applications regarding unlicensed Cannabis-Based Products for Medicinal Use (CBPMs) have been received by your Drug and Therapeutic Committee, or a similar clinical governance body? Please exclude Sativex and Epidiolex.
a. Please provide the therapeutic indication for the applications received e.g. chronic pain
b. Please detail from which department the request originated?
2. Of the total number of applications to your Drug and Therapeutic Committee, or a similar clinical governance body, how many applications for unlicensed CBPMs has the Trust declined since 1 November 2018? Please provide any details as to the reason/s behind declining the applications.
3. Of the total number of applications to your Drug and Therapeutic Committee, or a similar clinical governance body, how many applications for unlicensed CBPMs has the Trust accepted since 1 November 2018? Please provide any details of the application accepted where possible, including the cost of reimbursement and the product/s prescribed.
a. Please provide the therapeutic indication for the applications received e.g. chronic pain
b. Please detail from which department the request originated?
4. For applications to your Drug and Therapeutic Committee, or a similar clinical governance body, that have been accepted, please advise what the subsequent stage was (if there was one)? E.g. an Individual Funding Request being submitted or new entries being added to the Trust Formulary.
5. Please clarify whether funding for unlicensed Cannabis-Based Products for Medicinal Use is at CCG or Trust level?
6. Please clarify whether your Trust operates a policy with a capped number of prescriptions or duration of prescriptions for unlicensed Cannabis-Based Products for Medicinal Use?

Download response Unlicensed cannabis-based products. 210420